Evidence map›Paper›PMID 39417209›Full record

Trial reportJournal of clinical pharmacology2025

Exposure-Efficacy Analysis and Dopamine D2 Receptor Occupancy in Adults with Schizophrenia after Treatment with the Monthly Intramuscular Injectable Risperidone ISM.

Andreas Lindauer, Eric Snoeck, Christian Laveille, Ignacio Ayani, Lourdes Ochoa Díaz de Monasterioguren, Marcos Almendros, Javier Martínez-González, Lourdes Anta, Ibón Gutierro

Abstract readClinical Trial, Phase IIIRandomized Controlled Trial
PubMed Full text at PMC Publisher
In one paragraph

Trial report in Journal of clinical pharmacology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Andreas LindauerCalvagone SAS, Chazay d'Azergues, France.
Eric SnoeckLuccio bv, Rozenlaan 26, Retie, 2470, Belgium.
Christian LaveilleCalvagone SAS, Chazay d'Azergues, France.
Ignacio AyaniLaboratorios Farmaceuticos ROVI, S.A., Alfonso Gómez, Madrid, Spain.
Lourdes Ochoa Díaz de MonasteriogurenLaboratorios Farmaceuticos ROVI, S.A., Alfonso Gómez, Madrid, Spain.
Marcos AlmendrosLaboratorios Farmaceuticos ROVI, S.A., Alfonso Gómez, Madrid, Spain.
Javier Martínez-GonzálezLaboratorios Farmaceuticos ROVI, S.A., Alfonso Gómez, Madrid, Spain.ORCID 0000-0001-6314-4480
Lourdes AntaLaboratorios Farmaceuticos ROVI, S.A., Alfonso Gómez, Madrid, Spain.ORCID 0000-0001-5981-1850
Ibón GutierroLaboratorios Farmaceuticos ROVI, S.A., Alfonso Gómez, Madrid, Spain.

Funding

Laboratorios Farmacéuticos Rovi
6 · The paper itself

Abstract

Dopamine D2 receptor occupancy (D2RO) significantly influences the clinical effectiveness and safety of many antipsychotic drugs. Maintaining a D2RO range of 65%-80% provides the best antipsychotic effects while minimizing adverse reactions. Data from a Phase III trial were used to establish an exposure-response relationship for monthly intramuscular Risperidone ISM (75 and 100 mg) or placebo administered to adults with schizophrenia. Pharmacodynamic analysis was based on an E

Indexed as

Antipsychotic AgentsReceptors, Dopamine D2RisperidoneSchizophreniaAdultDose-Response Relationship, DrugDouble-Blind MethodFemaleHumansInjections, IntramuscularMaleMiddle AgedModels, BiologicalYoung AdultAntipsychotic AgentsReceptors, Dopamine D2Risperidonedopamine D2 receptor occupancymodeling and simulationPANSSpopulation PK/PDRisperidone ISMschizophrenia

Identifiers

PMID39417209
PMCPMC11867924

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.